Pyrazolylaminopyridines as inhibitors of FAK
View Patent ↗The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 11 , R 12 , R 13 , Q, Z, and p are as described herein. Compounds of the present invention are useful for the treatment of cancers.
1. A compound that is:
2-[(5-Chloro-2-{[3-methyl-1-(1-methylethyl)-1H-pyrazol-5-yl]amino}-4-pyridinyl)amino]-N-(methyloxy)benzamide;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 that is:
2-[(5-Chloro-2-{[3-methyl-1-(1-methylethyl)-1H-pyrazol-5-yl]amino}-4-pyridinyl)amino]-N-(methyloxy)benzamide.
3. A pharmaceutical composition comprising a compound according to claim 1 and one or more pharmaceutically acceptable carriers, diluents or excipients.
4. A pharmaceutical composition comprising the compound according to claim 2 and one or more pharmaceutically acceptable carriers, diluents or excipients.
5. A process for preparing a pharmaceutical composition containing a pharmaceutically acceptable carrier and the compound of claim 1 which process comprises bringing the compound of claim 1 into association with one or more pharmaceutically acceptable carriers, diluents or excipients.
6. A pharmaceutical composition according to claim 3 , wherein the composition is in tablet form.
7. A pharmaceutical composition according to claim 4 , wherein the composition is in tablet form.
8. A compound that is:
9. A pharmaceutical composition comprising the compound according to claim 8 and one or more pharmaceutically acceptable carriers, diluents or excipients.
10. A pharmaceutical composition according to claim 9 , wherein the composition is in tablet form.
11. A process for preparing a pharmaceutical composition containing a pharmaceutically acceptable carrier and the compound of claim 8 which process comprises bringing the compound of claim 8 into association with the pharmaceutically acceptable carrier.